, , .

, , . . , , . .. :PTC TherapeuticsAcceleron / ShireProsensaGSKAVI BiopharmaNovartisHalo Therapeutics

3

9

19 ()

, 45-53 ~65-72% ~85 % , ~25-30%, 2-20 ~5-10% ~13-15%

/ / / /

Tuffery-Giraud , 2009, 2,411 , 2,084 , 2,046 96% 93% .

Magri , 2011, .320 (205 115 ) (, , ),

Magri , 2011, .320 (205 115 ) ( 45) ), , IQ (p = 0.005). , (p = 0.0046).

Daguerre , 2009, . n=75 ( , 20%): ; B ( , 28%): ; C ( , 22%): D ( , 30%):

Daguerre , 2009, . . 30 D, / (IQ> 71: 7.7, 95%CI 1.6-20.4, p 0.003). , " 2 " ( 0.93, 0.98).

- (SPP1, OPN). OPN . (TT) (CQMS), (10 ) , (GT, GG)

- , .Eric P Hoffman, Elena Pegoraro, . FAMuSS CINRG - , , , , , (EP), , (), (PC), Davis (CMcD)

Flanigan . 2012 SPP1 ( ) , TGF , .

Flanigan . 2012, A XXXXX 50% , B . , , , 12.5 3.2 , , 10.5 2.2 .

CINRG

CINRG

CINRG . : 2-4 ( 5-60, , / ( ), , 5-30 - , > 5x - , , . : , , 16 , 13

: , , , : , 3, 6, 9, 12: / / MRC MMT / (CINRG CQMT) ( 10M )Brooke / Vignos (, 1, , MIP, MEP) , 5 ~ 1700 - , .

(